ShangBay Capital

ShangBay Capital is a U.S.-based venture capital firm based in Palo Alto, California (Silicon Valley). The firm invests in life-sciences, medical devices, biotechnology, and mobile-healthcare sectors. The firm's name ''ShangBay'' combines ''Shang'' (likely referencing Shanghai or the Chinese business-cultural a* / ''commerce'' character) with ''Bay'' (San Francisco Bay Area), suggesting a China-U.S. cross-border investment thesis. The firm operates at the intersection of U.S. Silicon Valley biomedical innovation and Chinese-market commercialisation / capital access. Detailed public information including precise aggregate AUM, named general partners, SEC / California-registered-investment-adviser status, fund vintages, and comprehensive portfolio-company disclosures is partially documented in mainstream financial-industry databases for this specific URL. The firm's operating environment has been affected by post-2020 U.S.-China biotech / life-sciences investment-and-technology-decoupling trends (including the BIOSECURE Act and CFIUS restrictions on cross-border life-sciences investment). The row should be noted as Active with moderate disclosure.